These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 34204146)

  • 1. Chemokines in Severe Cutaneous Adverse Reactions (SCARs).
    Miyagawa F; Asada H
    Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34204146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression profile of Th1/Th2-associated chemokines characterizes Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS) as distinct entities.
    Miyagawa F; Hasegawa A; Imoto K; Ogawa K; Kobayashi N; Ito K; Fujita H; Aihara M; Watanabe H; Sueki H; Tohyama M; Asada H
    Eur J Dermatol; 2015; 25(1):87-9. PubMed ID: 25547780
    [No Abstract]   [Full Text] [Related]  

  • 3. Cicatrizing Conjunctivitis in a Patient Diagnosed With Drug Reaction With Eosinophilia and Systemic Symptoms/Drug-Induced Hypersensitivity Syndrome but With Features of Stevens-Johnson Syndrome.
    Bohm KJ; Ciralsky JB; Harp JL; Bajaj S; Sippel KC
    Cornea; 2016 Jun; 35(6):888-91. PubMed ID: 27078005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interferon-γ-induced protein 10/CXCR3 axis is associated with human herpesvirus-6 reactivation and the development of sequelae in drug reaction with eosinophilia and systemic symptoms.
    Yang CW; Cho YT; Hsieh YC; Hsu SH; Chen KL; Chu CY
    Br J Dermatol; 2020 Nov; 183(5):909-919. PubMed ID: 32037509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS).
    Ogawa K; Morito H; Hasegawa A; Daikoku N; Miyagawa F; Okazaki A; Fukumoto T; Kobayashi N; Kasai T; Watanabe H; Sueki H; Iijima M; Tohyama M; Hashimoto K; Asada H
    J Dermatol Sci; 2013 Jan; 69(1):38-43. PubMed ID: 23141052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Soluble OX40 as a Diagnostic and Prognostic Biomarker for Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms.
    Mitsui Y; Shinkuma S; Nakamura-Nishimura Y; Ommori R; Ogawa K; Miyagawa F; Mori Y; Tohyama M; Asada H
    J Allergy Clin Immunol Pract; 2022 Feb; 10(2):558-565.e4. PubMed ID: 34757063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations.
    Teraki Y; Shibuya M; Izaki S
    Clin Exp Dermatol; 2010 Oct; 35(7):723-8. PubMed ID: 19874350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum osteopontin levels in patients with severe cutaneous adverse drug reactions.
    Suzuki M; Koshikawa S; Watanabe H; Inomata N; Yamaguchi Y; Aihara M; Sueki H
    J Dermatol; 2023 Apr; 50(4):536-540. PubMed ID: 36540013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring the acute response in severe hypersensitivity reactions to drugs.
    Shiohara T; Mizukawa Y; Aoyama Y
    Curr Opin Allergy Clin Immunol; 2015 Aug; 15(4):294-9. PubMed ID: 26110678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Perspective Regarding the Immunopathogenesis of Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms (DIHS/DRESS).
    Miyagawa F; Asada H
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal analysis of antibody profiles against plakins in severe drug eruptions: emphasis on correlation with tissue damage in drug-induced hypersensitivity syndrome and drug reaction with eosinophilia and systemic symptoms.
    Takehara A; Aoyama Y; Kurosawa M; Shirafuji Y; Umemura H; Kamiya K; Ushigome Y; Kano Y; Shiohara T; Iwatsuki K
    Br J Dermatol; 2016 Nov; 175(5):944-952. PubMed ID: 27087170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Undiagnosed and Rare Diseases in Critical Care: Severe Mucocutaneous Medication Reactions.
    Shields BE; Wanat KA; Chiu YE
    Crit Care Clin; 2022 Apr; 38(2):243-269. PubMed ID: 35369946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome.
    Ishida T; Kano Y; Mizukawa Y; Shiohara T
    Allergy; 2014 Jun; 69(6):798-805. PubMed ID: 24749495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions.
    Orime M
    J Immunol Res; 2017; 2017():6928363. PubMed ID: 29226159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review.
    Cheng CY; Su SC; Chen CH; Chen WL; Deng ST; Chung WH
    J Immunol Res; 2014; 2014():565320. PubMed ID: 24901010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis).
    Owen CE; Jones JM
    Med Clin North Am; 2021 Jul; 105(4):577-597. PubMed ID: 34059239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study.
    Dibek Misirlioglu E; Guvenir H; Bahceci S; Haktanir Abul M; Can D; Usta Guc BE; Erkocoğlu M; Toyran M; Nacaroglu HT; Civelek E; Buyuktiryaki B; Ginis T; Orhan F; Kocabas CN
    J Allergy Clin Immunol Pract; 2017; 5(3):757-763. PubMed ID: 28351788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe cutaneous adverse reactions: A 5-year retrospective study at Hospital Melaka, Malaysia, from December 2014 to February 2020.
    Tee CT; Abdullah NH; Kristummoonthy P; Lee CS
    Med J Malaysia; 2022 Jul; 77(4):409-414. PubMed ID: 35902928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of HLA genotypes with phenytoin induced severe cutaneous adverse drug reactions in Thai children.
    Manuyakorn W; Likkasittipan P; Wattanapokayakit S; Suvichapanich S; Inunchot W; Wichukchinda N; Khongkhatithuml C; Thampratankul L; Kamchaisatian W; Benjaponpitak S; Mahasirimongkol S
    Epilepsy Res; 2020 May; 162():106321. PubMed ID: 32272329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential cytokine profiles produced by anti-epileptic drug re-exposure of peripheral blood mononuclear cells derived from severe anti-epileptic drug patients and non-allergic controls.
    Srinoulprasert Y; Kumkamthornkul P; Tuchinda P; Wongwiangjunt S; Sathornsumetee S; Jongjaroenprasert K; Kulthanan K
    Cytokine; 2022 Sep; 157():155951. PubMed ID: 35772364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.